Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
As EU works to coordinate response to China’s COVID wave, Beijing and airlines are unhappy
08:15pm, Wednesday, 04'th Jan 2023 MarketWatch
EU officials are working to coordinate a response to China's current wave of COVID cases and are likely to mandate tests for travelers.
Merck Vs. Pfizer: Why Analyst Upgrades One Pharmaceutical Stock, While Downgrading Another
06:22pm, Wednesday, 04'th Jan 2023 Benzinga
The health care sector held up relatively well in a difficult year for stocks in 2022. On Wednesday, one analyst adjusted his coverage of two large cap pharmaceutical stocks heading into what could be
Deciphera (DCPH) Issues Strategic & Corporate Outlook for 2023
05:16pm, Wednesday, 04'th Jan 2023 Zacks Investment Research
Deciphera (DCPH) provides a strategic outlook and planned corporate milestones for 2023. The company also posts preliminary fourth-quarter and 2022 revenues.
Why Pfizer (PFE) Could Beat Earnings Estimates Again
05:10pm, Wednesday, 04'th Jan 2023 Zacks Investment Research
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023
03:01pm, Wednesday, 04'th Jan 2023 Benzinga
Upgrades
UBS upgraded the previous rating for Trane Technologies PLC (NYSE:TT) from Neutral to Buy. For the third quarter, Trane Technologies had an EPS of $2.27, compared to year-ago quarter EPS of $
Worried About 2023? Here's a Safer Way to Invest in Stocks This Year
02:37pm, Wednesday, 04'th Jan 2023 The Motley Fool
By holding a broad range of stocks and spreading out your investment over the year, you can minimize your overall risk.
As COVID vaccine and Paxlovid sales decline, analysts want to know what's next for Pfizer
02:05pm, Wednesday, 04'th Jan 2023
Pfizer PFE, -2.36% is the latest pandemic stock to face questions about its long-term strategy as revenue from its COVID-19 vaccine and antiviral business starts to dry up.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
01:50pm, Wednesday, 04'th Jan 2023 Zacks Investment Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why Pfizer (PFE) Could Beat Earnings Estimates Again
01:32pm, Wednesday, 04'th Jan 2023
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How 'Covid Darling' Pfizer Became A 'Show Me' Story For 2023
12:01pm, Wednesday, 04'th Jan 2023
Pfizer stock tumbled Wednesday after an analyst downgraded it, saying the "Covid darling" is now a "show me" story as sales crumble. The post How 'Covid Darling' Pfizer Became A 'Show Me' Story For 20
2 Analyst Calls to Have on Your Radar
10:45am, Wednesday, 04'th Jan 2023
Analysts are getting in some key calls early in the new year.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
10:32am, Wednesday, 04'th Jan 2023
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Pfizer (PFE) Gains As Market Dips: What You Should Know
10:45pm, Tuesday, 03'rd Jan 2023 Zacks Investment Research
In the latest trading session, Pfizer (PFE) closed at $51.26, marking a +0.04% move from the previous day.
Tesla stock wipes out three day bounce, hits lowest price in more than 2 years
09:44pm, Tuesday, 03'rd Jan 2023 MarketWatch
Tesla stock falls to fresh lows after disappointing deliveries data, to knock the EV maker down to 15th on list of most valuable S&P 500 index companies.
This Pneumococcal Vaccine Player Is The Top Pick For 2023 For This Analyst
05:34pm, Tuesday, 03'rd Jan 2023 Benzinga
Vaxcyte Inc (NASDAQ: PCVX) is Needham's top pick for 2023 and has been added to the Needham Conviction list and raised the price target to $58 from $52.
The analyst writes that the positive initial
